-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
35 ，4，。，2020140。，。
：
Xa，，，。2020、91.
68、49.
49，141.
17。
68、49.
49，141.
17。
Although apixaban's domestic market is still small, in recent years , the terminal sales of Chinese urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and physical pharmacies in Chinese cities have increased fast.
According to data from Mi Nei.
com, in 2019, the sales of apixaban in physical pharmacies in Chinese cities were 8.
09 million yuan, an increase of 2596.
89% year-on-year.
Sales in 2020 are expected to be 23.
89 million yuan, an increase of 195.
35% year-on-year.
According to data from Mi Nei.
com, in 2019, the sales of apixaban in physical pharmacies in Chinese cities were 8.
09 million yuan, an increase of 2596.
89% year-on-year.
Sales in 2020 are expected to be 23.
89 million yuan, an increase of 195.
35% year-on-year.
Sales of apixaban in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Apixaban sheet for the third Jicai varieties, Qilu Pharmaceutical, Stockhausen medicine, Jiayi medicine and Chia Tai Pharmaceutical Group and other four companies won the tender and carve up the market.
At present, 10 companies have been approved for production of Apixaban tablets, including Kelun Pharmaceutical, Wanbang Pharmaceutical, Dongyang Pharmaceutical, Better Pharmaceutical, Qingfeng Pharmaceutical, etc.
At present, 10 companies have been approved for production of Apixaban tablets, including Kelun Pharmaceutical, Wanbang Pharmaceutical, Dongyang Pharmaceutical, Better Pharmaceutical, Qingfeng Pharmaceutical, etc.
Apixaban tablets reviewed companies
Source: Mi Nei Net Consistency Evaluation Database
As a blockbuster drug on the list of TOP10 global sales, apixaban tablets have many imitation companies in the domestic market.
On February 27, Hanrui Pharmaceutical's application for the listing of apixaban tablets was accepted by the CDE.
At present, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, Lepu Pharmaceutical.
.
.
21 pharmaceutical companies submitted apixaban tablet listing applications according to the new registration classification are under review and approval.
Hisun Pharmaceutical's registration status for this product has been changed to "under approval", if it is successfully approved, it will be deemed as over-evaluated.
On February 27, Hanrui Pharmaceutical's application for the listing of apixaban tablets was accepted by the CDE.
At present, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, Lepu Pharmaceutical.
.
.
21 pharmaceutical companies submitted apixaban tablet listing applications according to the new registration classification are under review and approval.
Hisun Pharmaceutical's registration status for this product has been changed to "under approval", if it is successfully approved, it will be deemed as over-evaluated.
Source: Minet database
Medical Network News, March 5 Recently, Hisun Pharmaceutical entered the administrative examination and approval stage with the imitation of apixaban tablets for production in Category 4, and it is expected to be approved for listing in the near future.
Apixaban is a new type of oral anticoagulant drug.
In 2020, the global sales of the original research drug exceeded 14 billion U.
S.
dollars.
Although apixaban tablets have been included in the third batch of centralized procurement, there are still many domestic pharmaceutical companies actively deploying.
Apixaban is a new type of oral anticoagulant drug.
In 2020, the global sales of the original research drug exceeded 14 billion U.
S.
dollars.
Although apixaban tablets have been included in the third batch of centralized procurement, there are still many domestic pharmaceutical companies actively deploying.
Source: official website of the State Food and Drug Administration
Apixaban is a highly selective direct factor Xa inhibitor jointly developed by Bristol-Myers Squibb and Pfizer.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
.
In 2020, the global sales of Bristol-Myers Squibb and Pfizer’s apixaban tablets were 9.
168 billion U.
S.
dollars and 4.
949 billion U.
S.
dollars, for a total of 14.
117 billion U.
S.
dollars.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
.
In 2020, the global sales of Bristol-Myers Squibb and Pfizer’s apixaban tablets were 9.
168 billion U.
S.
dollars and 4.
949 billion U.
S.
dollars, for a total of 14.
117 billion U.
S.
dollars.
Although apixaban's domestic market is still small, in recent years , the terminal sales of Chinese urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and physical pharmacies in Chinese cities have increased fast.
According to data from Mi Nei.
com, in 2019, the sales of apixaban in physical pharmacies in Chinese cities were 8.
09 million yuan, an increase of 2596.
89% year-on-year.
Sales in 2020 are expected to be 23.
89 million yuan, an increase of 195.
35% year-on-year.
According to data from Mi Nei.
com, in 2019, the sales of apixaban in physical pharmacies in Chinese cities were 8.
09 million yuan, an increase of 2596.
89% year-on-year.
Sales in 2020 are expected to be 23.
89 million yuan, an increase of 195.
35% year-on-year.
Sales of apixaban in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Apixaban sheet for the third Jicai varieties, Qilu Pharmaceutical, Stockhausen medicine, Jiayi medicine and Chia Tai Pharmaceutical Group and other four companies won the tender and carve up the market.
At present, 10 companies have been approved for production of Apixaban tablets, including Kelun Pharmaceutical, Wanbang Pharmaceutical, Dongyang Pharmaceutical, Better Pharmaceutical, Qingfeng Pharmaceutical, etc.
At present, 10 companies have been approved for production of Apixaban tablets, including Kelun Pharmaceutical, Wanbang Pharmaceutical, Dongyang Pharmaceutical, Better Pharmaceutical, Qingfeng Pharmaceutical, etc.
Apixaban tablets reviewed companies
Source: Mi Nei Net Consistency Evaluation Database
As a blockbuster drug on the list of TOP10 global sales, apixaban tablets have many imitation companies in the domestic market.
On February 27, Hanrui Pharmaceutical's application for the listing of apixaban tablets was accepted by the CDE.
At present, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, Lepu Pharmaceutical.
.
.
21 pharmaceutical companies submitted apixaban tablet listing applications according to the new registration classification are under review and approval.
Hisun Pharmaceutical's registration status for this product has been changed to "under approval", if it is successfully approved, it will be deemed as over-evaluated.
On February 27, Hanrui Pharmaceutical's application for the listing of apixaban tablets was accepted by the CDE.
At present, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, Lepu Pharmaceutical.
.
.
21 pharmaceutical companies submitted apixaban tablet listing applications according to the new registration classification are under review and approval.
Hisun Pharmaceutical's registration status for this product has been changed to "under approval", if it is successfully approved, it will be deemed as over-evaluated.
Source: Minet database
Medical Network News, March 5 Recently, Hisun Pharmaceutical entered the administrative examination and approval stage with the imitation of apixaban tablets for production in Category 4, and it is expected to be approved for listing in the near future.
Apixaban is a new type of oral anticoagulant drug.
In 2020, the global sales of the original research drug exceeded 14 billion U.
S.
dollars.
Although apixaban tablets have been included in the third batch of centralized procurement, there are still many domestic pharmaceutical companies actively deploying.
Apixaban is a new type of oral anticoagulant drug.
In 2020, the global sales of the original research drug exceeded 14 billion U.
S.
dollars.
Although apixaban tablets have been included in the third batch of centralized procurement, there are still many domestic pharmaceutical companies actively deploying.
Source: official website of the State Food and Drug Administration
Apixaban is a highly selective direct factor Xa inhibitor jointly developed by Bristol-Myers Squibb and Pfizer.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
.
In 2020, the global sales of Bristol-Myers Squibb and Pfizer’s apixaban tablets were 9.
168 billion U.
S.
dollars and 4.
949 billion U.
S.
dollars, for a total of 14.
117 billion U.
S.
dollars.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
.
In 2020, the global sales of Bristol-Myers Squibb and Pfizer’s apixaban tablets were 9.
168 billion U.
S.
dollars and 4.
949 billion U.
S.
dollars, for a total of 14.
117 billion U.
S.
dollars.
Although apixaban's domestic market is still small, in recent years , the terminal sales of Chinese urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and physical pharmacies in Chinese cities have increased fast.
According to data from Mi Nei.
com, in 2019, the sales of apixaban in physical pharmacies in Chinese cities were 8.
09 million yuan, an increase of 2596.
89% year-on-year.
Sales in 2020 are expected to be 23.
89 million yuan, an increase of 195.
35% year-on-year.
Hospital hospital hospital pharmacy pharmacy pharmacyAccording to data from Mi Nei.
com, in 2019, the sales of apixaban in physical pharmacies in Chinese cities were 8.
09 million yuan, an increase of 2596.
89% year-on-year.
Sales in 2020 are expected to be 23.
89 million yuan, an increase of 195.
35% year-on-year.
Sales of apixaban in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Apixaban sheet for the third Jicai varieties, Qilu Pharmaceutical, Stockhausen medicine, Jiayi medicine and Chia Tai Pharmaceutical Group and other four companies won the tender and carve up the market.
At present, 10 companies have been approved for production of Apixaban tablets, including Kelun Pharmaceutical, Wanbang Pharmaceutical, Dongyang Pharmaceutical, Better Pharmaceutical, Qingfeng Pharmaceutical, etc.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise EnterpriseAt present, 10 companies have been approved for production of Apixaban tablets, including Kelun Pharmaceutical, Wanbang Pharmaceutical, Dongyang Pharmaceutical, Better Pharmaceutical, Qingfeng Pharmaceutical, etc.
Apixaban tablets reviewed companies
Source: Mi Nei Net Consistency Evaluation Database
As a blockbuster drug on the list of TOP10 global sales, apixaban tablets have many imitation companies in the domestic market.
On February 27, Hanrui Pharmaceutical's application for the listing of apixaban tablets was accepted by the CDE.
At present, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, Lepu Pharmaceutical.
.
.
21 pharmaceutical companies submitted apixaban tablet listing applications according to the new registration classification are under review and approval.
Hisun Pharmaceutical's registration status for this product has been changed to "under approval", if it is successfully approved, it will be deemed as over-evaluated.
On February 27, Hanrui Pharmaceutical's application for the listing of apixaban tablets was accepted by the CDE.
At present, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, Lepu Pharmaceutical.
.
.
21 pharmaceutical companies submitted apixaban tablet listing applications according to the new registration classification are under review and approval.
Hisun Pharmaceutical's registration status for this product has been changed to "under approval", if it is successfully approved, it will be deemed as over-evaluated.
Source: Minet database
